Details for Patent: 6,515,117
✉ Email this page to a colleague
Which drugs does patent 6,515,117 protect, and when does it expire?
Patent 6,515,117 protects QTERNMET XR, QTERN, BYDUREON, BYDUREON PEN, BYDUREON BCISE, XIGDUO XR, and FARXIGA, and is included in six NDAs.
Protection for BYDUREON has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and fourteen patent family members in forty-one countries.
Summary for Patent: 6,515,117
| Title: | C-aryl glucoside SGLT2 inhibitors and method |
| Abstract: | An SGLT2 inhibiting compound is provided having the formula ##STR1## A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent. |
| Inventor(s): | Ellsworth; Bruce (Princeton, NJ), Washburn; William N. (Titusville, NJ), Sher; Philip M. (Plainsboro, NJ), Wu; Gang (Princeton, NJ), Meng; Wei (Pennington, NJ) |
| Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
| Application Number: | 10/151,436 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,515,117 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 6,515,117
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | QTERNMET XR | dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 210874-001 | May 2, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Sign Up | ||
| Astrazeneca Ab | QTERNMET XR | dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 210874-002 | May 2, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Sign Up | ||
| Astrazeneca Ab | QTERNMET XR | dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 210874-003 | May 2, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Sign Up | ||
| Astrazeneca Ab | QTERNMET XR | dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 210874-004 | May 2, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Sign Up | ||
| Astrazeneca Ab | QTERN | dapagliflozin; saxagliptin hydrochloride | TABLET;ORAL | 209091-002 | May 2, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 6,515,117
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1506211 | ⤷ Sign Up | C300585 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1506211 | ⤷ Sign Up | PA2013008 | Lithuania | ⤷ Sign Up |
| European Patent Office | 1506211 | ⤷ Sign Up | 122013000033 | Germany | ⤷ Sign Up |
| European Patent Office | 1506211 | ⤷ Sign Up | C20130006 00074 | Estonia | ⤷ Sign Up |
| European Patent Office | 1506211 | ⤷ Sign Up | 92182 | Luxembourg | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
